Complete response to immune checkpoint inhibitors in kidney cancer patients
A recent meta-analysis of 6 randomised phase II and III [...]
Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer
In this phase 1b study, he researchers were looking for [...]
Bacteria in the gut linked to efficacy of immunotherapy
In this study, the investigators looked at the different types [...]
Sarcopenia is prevalent in kidney cancer patients treated with cabozantinib
Sarcopenia is the loss of muscle mass along with reduced [...]
Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued [...]
Treatment of kidney cancer during the coronavirus pandemic
COVID-19 continues to affect the care of patients with metastatic [...]
Pazopanib for poor risk kidney cancer patients
Pazopanib is used for first-line metastatic RCC treatment, but the [...]
Outcomes of complete metastasectomy in metastastic kidney cancer
A recent study from Canada investigated the use of surgery [...]
Biomarkers for kidney cancer: current and future strategies
An educational symposium was held from 8-10 August as part [...]
First-line therapy for metastatic kidney cancer: Is two better than one?
An educational symposium was held from 8-10 August as part [...]
